{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T09:07:15Z","timestamp":1770714435822,"version":"3.49.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,9]],"date-time":"2024-06-09T00:00:00Z","timestamp":1717891200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiology Case Reports"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.radcr.2024.06.025","type":"journal-article","created":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T12:11:56Z","timestamp":1720872716000},"page":"4049-4054","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Palbociclib and fulvestrant combined regimen induced prolonged bone metastasis control of stage IV HR+\/HER2- breast cancer: A case report"],"prefix":"10.1016","volume":"19","author":[{"given":"Rand K.","family":"Jadallah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed H.","family":"Al Sharie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saja M.","family":"Alzghoul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jawad M.","family":"Al-Karaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad S. Bani","family":"Amer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1344-6743","authenticated-orcid":false,"given":"Tariq H.","family":"Rawashdeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osama","family":"Alshari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10074","key":"10.1016\/j.radcr.2024.06.025_bib0001","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S0140-6736(16)31891-8","article-title":"Breast cancer","volume":"389","author":"Harbeck","year":"2017","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.radcr.2024.06.025_bib0002","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.3390\/curroncol28030168","article-title":"Current landscape of targeted therapy in hormone receptor-positive and HER2-negative breast cancer","volume":"28","author":"Andrahennadi","year":"2021","journal-title":"Curr Oncol"},{"issue":"3","key":"10.1016\/j.radcr.2024.06.025_bib0003","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1505270","article-title":"Palbociclib in hormone-receptor-positive advanced breast Cancer","volume":"373","author":"Turner","year":"2015","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.radcr.2024.06.025_bib0004","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.radcr.2024.06.025_bib0005","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40265-020-01461-2","article-title":"Inhibiting CDK4\/6 in breast cancer with palbociclib, ribociclib, and abemaciclib: similarities and differences","volume":"81","author":"Braal","year":"2021","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.radcr.2024.06.025_bib0006","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s10549-017-4385-3","article-title":"Cyclin-dependent kinase 4\/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib","volume":"166","author":"Kwapisz","year":"2017","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"10.1016\/j.radcr.2024.06.025_bib0007","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","volume":"17","author":"Cristofanilli","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radcr.2024.06.025_bib0008","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.semcancer.2019.08.012","article-title":"Metastatic heterogeneity of breast cancer: molecular mechanism and potential therapeutic targets","volume":"60","author":"Liang","year":"2020","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.radcr.2024.06.025_bib0009","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.biocel.2018.01.003","article-title":"Breast cancer bone metastases: pathogenesis and therapeutic targets","volume":"96","author":"Brook","year":"2018","journal-title":"Int J Biochem Cell Biol"},{"issue":"11","key":"10.1016\/j.radcr.2024.06.025_bib0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0260066","article-title":"Diagnosis of bone metastases in breast cancer: lesion-based sensitivity of dual-time-point FDG-PET\/CT compared to low-dose CT and bone scintigraphy","volume":"16","author":"Hansen","year":"2021","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.radcr.2024.06.025_bib0011","first-page":"376","article-title":"Palbociclib plus letrozole induces a complete metabolic response in metastatic breast cancer patient with idiopathic thrombocytopenia","volume":"113","author":"Barberi","year":"2022","journal-title":"Recenti Prog Med"},{"issue":"14","key":"10.1016\/j.radcr.2024.06.025_bib0012","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000025175","article-title":"Palbociclib with letrozole as second-line neo-systemic therapy after failure of neo-adjuvant chemotherapy for luminal type breast cancer: a case report","volume":"100","author":"Jung","year":"2021","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"10.1016\/j.radcr.2024.06.025_bib0013","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.15419\/bmrat.v5i6.448","article-title":"Complete response of Palbociclib in metastatic breast cancer patient: a case report","volume":"5","author":"Payandeh","year":"2018","journal-title":"Biomed Res Ther"},{"issue":"3","key":"10.1016\/j.radcr.2024.06.025_bib0014","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1159\/000519567","article-title":"Surgery to oligometastatic breast cancer after excellent response to palbociclib and letrozole therapy: pitfall of ultrasound therapeutic evaluation","volume":"14","author":"Fujii","year":"2021","journal-title":"Case Rep Oncol"},{"issue":"4","key":"10.1016\/j.radcr.2024.06.025_bib0015","doi-asserted-by":"crossref","first-page":"BMT60","DOI":"10.2217\/bmt-2021-0006","article-title":"Palbociclib in a patient with HR+\/HER2-advanced breast cancer and HIV1 infection: a case report","volume":"10","author":"Canino","year":"2021","journal-title":"Breast Cancer Manag"},{"issue":"2","key":"10.1016\/j.radcr.2024.06.025_bib0016","article-title":"The role of cyclin-dependent kinase 4\/6 inhibitors treatment in oligometastatic breast cancer: a case report on a possible curative intent strategy","volume":"15","author":"Valente","year":"2023","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.radcr.2024.06.025_bib0017","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/s13256-023-03902-4","article-title":"Long-lasting complete remission in a patient with systemic metastases of recurrent breast cancer treated with cyclin-dependent kinases 4\/6 inhibitors: a case report","volume":"17","author":"Yoneto","year":"2023","journal-title":"J Med Case Rep"},{"issue":"3","key":"10.1016\/j.radcr.2024.06.025_bib0018","doi-asserted-by":"crossref","first-page":"e277","DOI":"10.1016\/j.clbc.2017.12.008","article-title":"Complete response to single-agent palbociclib in metastatic breast cancer: a case report","volume":"18","author":"Yeruva","year":"2018","journal-title":"Clin Breast Cancer"},{"issue":"5\u20136","key":"10.1016\/j.radcr.2024.06.025_bib0019","first-page":"158","article-title":"Rapid response of breast cancer cutaneous metastasis to single-agent palbociclib: a case report","volume":"65","author":"Droubi","year":"2021","journal-title":"Chemotherapy"},{"key":"10.1016\/j.radcr.2024.06.025_bib0020","first-page":"416","article-title":"Safety and efficacy of palbociclib in male meta-static breast cancer: a report of two cases","volume":"14","author":"Inoue","year":"2020","journal-title":"Ann Case Rep"},{"issue":"24","key":"10.1016\/j.radcr.2024.06.025_bib0021","doi-asserted-by":"crossref","first-page":"e33975","DOI":"10.1097\/MD.0000000000033975","article-title":"Trastuzumab, leuprorelin, letrozole, and palbociclib as first-line therapy in HER2-positive and hormone receptor-positive metastatic breast cancer: a case report","volume":"102","author":"Sun","year":"2023","journal-title":"Medicine (Baltimore)"}],"container-title":["Radiology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1930043324005144?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1930043324005144?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T09:16:23Z","timestamp":1733217383000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1930043324005144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S1930043324005144"],"URL":"https:\/\/doi.org\/10.1016\/j.radcr.2024.06.025","relation":{},"ISSN":["1930-0433"],"issn-type":[{"value":"1930-0433","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Palbociclib and fulvestrant combined regimen induced prolonged bone metastasis control of stage IV HR+\/HER2- breast cancer: A case report","name":"articletitle","label":"Article Title"},{"value":"Radiology Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radcr.2024.06.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of University of Washington.","name":"copyright","label":"Copyright"}]}}